Effectiveness of erenumab in chronic migraine in a tertiary headache centre

被引：0
|
作者：
Khalil, Modar [1 ,2 ]
Moreno-Ajona, David [1 ,2 ]
Greenwood, Fiona [1 ,2 ]
Hoffmann, Jan [1 ,2 ]
Goadsby, Peter J. [1 ,2 ]
机构：
[1] Kings Coll London, NIHR Wellcome Trust Kings Clin Res Facil, London, England
[2] Kings Coll London, SLaM Biomed Res Ctr, London, England
来源：
CEPHALALGIA | 2019年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
IHC-PO-412
引用
收藏
页码：269 / 270
页数：2
相关论文
共 50 条
  • [11] Migraine prophylactic treatment in a tertiary headache centre: A retrospective study
    Maestrini, Ilaria
    Giuliani, Giada
    Puma, Marta
    Vicenzini, Edoardo
    Altieri, Marta
    Di Piero, Vittorio
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429
  • [12] Menstrual Headache in Women with Chronic Migraine Treated with Erenumab: An Observational Case Series
    Ornello, Raffaele
    Frattale, Ilaria
    Caponnetto, Valeria
    De Matteis, Eleonora
    Pistoia, Francesca
    Sacco, Simona
    BRAIN SCIENCES, 2021, 11 (03)
  • [13] Assessment of the relative effectiveness of erenumab compared with onabotulinumtoxinA for the prevention of chronic migraine
    Mahon, Ronan
    Vo, Pamela
    Pannagl, Katharina
    Tiwari, Santosh
    Heemstra, Harald
    Ferraris, Matias
    Zhao, Jing
    Betts, Keith A.
    Proot, Pascal
    CURRENT MEDICAL RESEARCH AND OPINION, 2023, 39 (01) : 105 - 112
  • [14] Real-world effectiveness of fremanezumab in patients with refractory migraine from a US tertiary headache center who switched from erenumab
    Yuan, H.
    Hopkins, M.
    Driessen, M. T.
    Krasenbaum, L. J.
    Seminerio, M. J.
    Marmura, M. J.
    HEADACHE, 2022, 62 : 156 - 157
  • [15] Cost of chronic and episodic migraine patients in continuous treatment for two years in a tertiary level headache Centre
    Negro, Andrea
    Sciattella, Paolo
    Rossi, Daniele
    Guglielmetti, Martina
    Martelletti, Paolo
    Mennini, Francesco Saverio
    JOURNAL OF HEADACHE AND PAIN, 2019, 20 (01):
  • [16] Cost of chronic and episodic migraine patients in continuous treatment for two years in a tertiary level headache Centre
    Andrea Negro
    Paolo Sciattella
    Daniele Rossi
    Martina Guglielmetti
    Paolo Martelletti
    Francesco Saverio Mennini
    The Journal of Headache and Pain, 2019, 20
  • [17] First insights in real-world effectiveness of erenumab in chronic migraine patients with high burden of disease in Germany from the NTD headache and migraine registry
    Peikert, Andreas
    Koerwer, Monika
    Tozzi, Viola
    Dikow, Heidi
    Rossnagel, Fabian
    Schnabel, Silvio
    Braune, Stefan
    Bergmann, Arnfin
    NEUROLOGY, 2020, 94 (15)
  • [18] Pharmacological treatments in migraine patients: an overview from a tertiary headache centre
    Bolchini, M.
    di Cola, F. Schiano
    Caratozzolo, S.
    Rao, R.
    Liberini, P.
    Padovani, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 486 - 486
  • [19] The comorbidity of migraine and hypertension. A study in a tertiary care headache centre
    Prudenzano M.P.
    Monetti C.
    Merico L.
    Cardinali V.
    Genco S.
    Lamberti P.
    Livrea P.
    The Journal of Headache and Pain, 2005, 6 (4) : 220 - 222
  • [20] Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache
    Pensato, Umberto
    Baraldi, Carlo
    Favoni, Valentina
    Cainazzo, Maria Michela
    Torelli, Paola
    Querzani, Pietro
    Pascazio, Alessia
    Mascarella, Davide
    Matteo, Eleonora
    Quintana, Simone
    Asioli, Gian Maria
    Cortelli, Pietro
    Pierangeli, Giulia
    Guerzoni, Simona
    Cevoli, Sabina
    NEUROLOGICAL SCIENCES, 2022, 43 (02) : 1273 - 1280
12345